National Research (NASDAQ:NRC) Lowered to “Hold” Rating by Wall Street Zen

Wall Street Zen lowered shares of National Research (NASDAQ:NRC) from a buy rating to a hold rating in a report published on Saturday morning.

Several other research firms have also commented on NRC. Citizens Jmp boosted their price objective on shares of National Research from $23.00 to $26.00 and gave the stock a “market outperform” rating in a research note on Wednesday, July 29th. Weiss Ratings lowered shares of National Research from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, August 6th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, National Research currently has a consensus rating of “Hold” and an average price target of $26.00.

National Research Price Performance

Shares of NRC stock opened at $21.19 on Friday. National Research has a 1-year low of $11.01 and a 1-year high of $23.68. The stock’s 50-day moving average is $20.63 and its 200 day moving average is $18.24. The company has a market cap of $482.07 million, a P/E ratio of 84.76 and a beta of 0.34. The company has a debt-to-equity ratio of 13.13, a current ratio of 0.65 and a quick ratio of 0.65.

National Research (NASDAQ:NRC) last announced its earnings results on Tuesday, July 28th. The company reported $0.31 EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.46. The business had revenue of $35.39 million during the quarter, compared to the consensus estimate of $34.90 million. National Research had a net margin of 4.18% and a return on equity of 164.26%.

National Research Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 9th. Investors of record on Friday, September 25th will be paid a $0.16 dividend. The ex-dividend date is Friday, September 25th. This represents a $0.64 dividend on an annualized basis and a yield of 3.0%. National Research’s dividend payout ratio (DPR) is 256.00%.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Russell Investments Group Ltd. lifted its stake in shares of National Research by 85.6% during the third quarter. Russell Investments Group Ltd. now owns 1,997 shares of the company’s stock worth $26,000 after buying an additional 921 shares during the period. EverSource Wealth Advisors LLC increased its position in shares of National Research by 9,535.3% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,638 shares of the company’s stock valued at $28,000 after acquiring an additional 1,621 shares during the period. BNP Paribas Financial Markets raised its stake in National Research by 85.4% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,496 shares of the company’s stock worth $32,000 after acquiring an additional 1,150 shares during the last quarter. Strs Ohio purchased a new position in National Research in the 1st quarter worth $33,000. Finally, Raymond James Financial Inc. acquired a new stake in National Research during the 2nd quarter worth about $34,000. Institutional investors and hedge funds own 47.26% of the company’s stock.

National Research Company Profile

National Research Corp (NASDAQ: NRC), also known as NRC Health, is a healthcare analytics and performance improvement company specializing in patient and employee experience measurement. The company’s cloud-based platform enables healthcare providers to collect real-time feedback through patient satisfaction surveys, post-discharge outreach, and employee engagement tools. NRC Health integrates clinical, operational and financial data to deliver actionable insights that support quality improvement initiatives and value-based care programs.

Since its founding in the early 1990s and headquartered in Lincoln, Nebraska, National Research has expanded beyond its regional roots to serve more than 1,600 hospitals and 12,000 care sites across the United States and Canada.